HIV/AIDS treatment and care Clinical protocols for the WHO European Region



Protocol 4: Management of tuberculosis and HIV coinfection

Update

18 July 2008

Page 140, Table 1, for previously TB-treated patients, under column "Initial phase", should read as follows:

Table 1. Recommended TB treatment regimens for PLHIV with active TB

| Type of TB case | TB treatment regimen ^a | |
|---|--|--------------------|
| | Initial phase ^b | Continuation phase |
| New TB patient | HRZE 2 months ^c | HR 4 months |
| Previously TB-treated patient, including: relapse treatment after default treatment failure ^d | HRZES 2 months and after that HRZE 1 month | HRE 5 months |
| Chronic or MDR-TB cases (still sputum-positive after supervised re-treatment) | A specially designed regimen, whether standard or ad hoc | |

E: ethambutol; H: isoniazid; R: rifampicin; S: streptomycin; Z: pyrazinamide.

^a Daily TB treatment is recommended for HIV-positive patients with active TB.

^b Direct observation of drug intake is recommended during the entire course of therapy, particularly in the initial phase.

^c Streptomycin may be used instead of ethambutol. In meningeal TB, ethambutol should be replaced by streptomycin, which diffuses more in the meninges.

d Whenever possible, drug sensitivity testing should be done to enable an individualized treatment regimen.